Rua Bioscience Limited — Director's Dealing 2021

Dec 8, 2021

==> picture [57 x 17] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited; and
Name of listed issuer:		RuaBioscienceLimited
Date this disclosure made:		7-Dec-21
Date of last disclosure:		2-Nov-21
Director or senior managergiving disclosure
Full name(s):		Manu Caddie
Name of listed issuer:		Rua Bioscience Limited
Name of related body corporate (if applicable):
Position held in listed issuer:		Kaihautu - Head of Innovation and Regulationof Rua
Summary of acquisition or disposal of relevant interest (excluding specified derivative	s)
Class of affected quoted financial products:		Ordinary shares in Rua Bioscience Limited
Nature of the affected relevant interest(s):		Manu is a director and 50% shareholder of New Zealand Nutraceuticals Limited (NZNL). NZNL is a limited partner of Hikurangi Bioactives Limited Partnership (HBLP) with a 40% economic interest in HBLP. HBLP is the registered holder and beneficial owner of 17,616,591 (before the transactions) and 17,554,367 (after the transactions) ordinary shares in Rua BioscienceLimited.
For that relevant interest-
Number held in class before acquisition or disposal:		7,046,636
Number held in class after acquisition or disposal:		7,021,747
Current registered holder(s):	able	HBLP
Registered holder(s)once transfers are registered:		HBLP
Summary of acquisition or disposal of specified derivatives relevant interest (if applic		)
Type of affected derivative:		N/A
Class of underlyingfinancial products:		N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial products(if any):		N/A
A statement as to whether the derivative is cash settled or physicallysettled:		N/A
Maturitydate of the derivative(if any):		N/A
Expirydate of the derivative(if any):		N/A
Theprice specified in the terms of the derivative(if any):		N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:		N/A
_For that derivative,- _		N/A
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:		5
Details of transactions requiring disclosure-		(a) 30 November 2021 (b) 1 December 2021 (c) 2 December 2021 (d) 3 December 2021 (e) 6December 2021
Date oftransaction:
Nature of transaction:		On market sale
Name ofany otherparty orparties to the transaction(if known):		Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:		(a) NZ$2,334.72 being 40% of proceeds of HBLP's sale of 14,592 shares for $5,836.80 (before any fees) (b) NZ$627.14 being 40% of proceeds of HBLP's sale of 3,876 shares for $1,567.84 (before any fees) (c) NZ$169.92 being 40% of proceeds of HBLP's sale of 1,062 shares for $424.80 (before any fees) (d) NZ$4,081.28 being 40% of proceeds of HBLP's sale of 25,508 shares for $10,203.20 (before any fees) (e) NZ$2,749.76 being 40% of proceeds of HBLP's sale of 17,186 for $6,874.40 (before any fees)
Numberof financialproducts towhichthe transaction related:		(a) 5,837 (being 40% of 14,592) (b) 1,550 (being 40% of 3,876) (c) 425 (being 40% of 1,062) (d) 10,203 (being 40% of 25,508) (e) 6,874(being40% of 17,186)
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Yes. Note, however, that Manu Caddie does not have control over HBLP's operational decisions as to whether to undertake these trades in Rua's shares.

No. Prior written clearance was not required as Manu Caddie does not have control over HBLP's operational decisions as to whether to undertake these trades in Rua's shares. N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products: Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:

Ordinary shares in Rua Bioscience Limited Registered and beneficial holder

194,106 Manu Caddie

N/A

Details of derivative

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A

N/A N/A N/A N/A

N/A N/A N/A

N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer:

Date of signature:

==> picture [16 x 20] intentionally omitted <==

7-Dec-21

or

Signature of person authorised to sign on behalf of director or officer: Date of signature: Name and title of authorised person:

==> picture [291 x 343] intentionally omitted <==